European Biopharmaceutical Review |
 |
|
|
|
|
 |
| |
|
|
EBR’s Editor, Dr Deborah O’Neil, details all the innovations touched upon in this issue and how some can enhance cancer treatment.
|
|
|
|
|
|
Biobanks and the Rise of Precision Medicines
Unlocking the Power of Data
Timo Kanninen at BC Platforms expresses the urgency surrounding data sharing, arguing that researchers need access to unique datasets if they wish to progress in personalised healthcare.
|
|
|
|
Batch Releases and Brexit
The Impact of Brexit on the Pharma Industry
As Brexit negotiations become more pressing and the deadline continues to loom, ‘red lines’ navigation and plans for a ‘no-deal’ scenario must be established urgently. Lynne Byers at NSF International offers guidance on the potential challenges.
|
|
|
|
|
Biopharma Investments in Scandinavia
Challenges for Small Businesses in the Global Pharma Market
The pharma industry has been forced to adapt over the years, going from a field deemed ‘safe’ and recession-proof to one of a constantly evolving and accelerating trajectory. Stephen McNeeney PhD at Potter Clarkson demonstrates how ever-increasing demands are moulding the industry.
|
|
|
|
Scandinavia: What is in a Name?
Spot the Difference
Defining Scandinavia is a bigger question than most would realise. Tórben Thers Nørgaard at PharmaLex Nordics delves into the regional differences in compliance and packaging to highlight where gaps in expertise exist.
|
|
|
|
Engineering Biopharmaceuticals to Address Intractable Diseases
Biopharmaceuticals for the Brain
Stephen James PhD, Erik Nordling PhD, and Stefan Svensson Gelius PhD at Sobi expand on how accomplishing therapeutically meaningful levels of biopharmaceuticals can be difficult to accomplish and why companies should consider exploring biological engineering to ease the process.
|
|
|
|
|
Drug Development Forecasts
Forecasting Development Stages to Stay Ahead of Compounds
Jamie Blackport and Chris Watson at Mirador Analytics recommend epidemiology-based forecasting to provide the best possible compound current value analysis available.
|
|
|
|
|
Encapsulation and Microfluidics
Channelling the Future of Liposome Generation
Damiano Rossi at Dolomite Microfluidics and Anna Blakney at Imperial College review drug encapsulation, a drug delivery method that has signficantly increased in usage given the protection they can offer enclosed molecules.
|
|
|
|
Drug Delivery to the Lungs
Thinking Throats with Anatomical Throat Models
The inhalation industry has largely welcomed anatomical throat models over the last few years. Samantha Holmes and Alex Slowey at 3M assess their utilisation, particularly in regard to in vivo testing.
|
|
|
|
|
|
Computed Tomography Imaging
The Advent of Nanoparticle Contrast Agents
New methods, namely using nanoparticle and targeted contrast agents, are paving the way for better treatment efficiency and personalised treatment plans in the cancer arena, claims Dr Hannah Prebble at MARS Bioimaging.
|
|
|
|
|
|
Minimal Residual Disease Assessment in Blood Cancers
Monitoring Malignancies Through Assay Development
Although progression in the drug development arena has improved prospects for blood cancers, companies should still consider assay-based methods to detect residual disease to ultimately improve patient care, suggests Ilan Kirsch at Adaptive Biotechnologies.
|
|
|
|
|
|
The War Against Microbes
Vaccine Victories Against Microbial Resistance
Dr Donald F Gerson, Jonas Elliott Gerson, Allison Turner, and Dr Gail Meadows at PnuVax address the pressing issue that is antibiotic resistance, explaining that, though humans are definitely winning the battle, difficult organisms remain which are proving arduous to combat.
|
|
|
|
Electron Beam- Sterilised Vaccines
Exploring Amino Acid-Based and Stable Spray-Dried Vaccines
Developing therapeutic biologics is no easy feat, as formulation issues act as a significant cause for drug development delays. The team at LEUKOCARE advise how best to approach the matter.
|
|
|
|
Stopping the Spread of Infectious Diseases
The Value of Vaccines
Incidents of Lyme disease have rapidly increased over the last few decades, making it, globally, a significant risk. Thomas Lingelbach at Valneva presents the case for a vaccine against the illness.
|
|
|
|
|
|
Q&A: New Targeted Treatments
Embracing a New Lease of Life
Genea Biocells’Alex Kiselyov discusses with EBR the myriad advantages that are associated with drug repurposing, particularly in the realm of molecular biophysics and targets.
|
|
|
|
Drug Repurposing for Infectious Diseases
Fighting the Damocles Sword of Infectious Diseases Through Drug Repurposing
Antimicrobial resistance poses a major challenge for the treatment of infectious diseases today. Andrés Pizzorno PhD at Signia Therapeutics explores how to address this from a drug repurposing perspective.
|
|
|
|
|
Ethical Considerations in Human Biospecimens
Consent and Biospecimen Collection in Human Research
Informed consent is one of many ethical considerations that must be made when handling human research subjects. Tony Brown PhD and Kelly Sapsford at BioIVT lend their expertise on what factors to be aware of to meet regulations.
|
|
|
|
Simplifying Regulatory Requirements
Compliance Complexity in the Data Management Landscape
Regulatory compliance may benefit from the adoption of a more holistic approach. Romauld Braun at AMPLEXOR is encouraging life sciences companies to review how they manage data in a time of increasing regulatory complexity.
|
|
|
|
|
In Brief
Gates and Doors
At the turn of the year, EBR’s Industry Advisor, Emile Bellott, reflects upon the progress made across biopharmaceutical sciences.
|
|
|
|
|
|
